KLKB1¹¹ KLKB1
Kallikrein B1 — encodes plasma prekallikrein (Fletcher factor), a serine protease that circulates in blood as an inactive zymogen complexed with high-molecular-weight kininogen (HK) is the central enzyme of the plasma contact activation pathway. When factor XII (Hageman factor)²² factor XII (Hageman factor)
the initiating serine protease of the intrinsic coagulation cascade, activated by contact with negatively charged surfaces is activated, it converts plasma prekallikrein into plasma kallikrein — an active protease with far-reaching effects on coagulation, inflammation, blood pressure, and vascular tone. The rs4253238 intronic variant in KLKB1 modulates how much plasma kallikrein activity the liver produces, with downstream consequences for bradykinin generation, endothelin regulation, and thrombotic risk.

The Mechanism

rs4253238 sits in an intron of KLKB1 on chromosome 4q35.2. Although it does not change the plasma prekallikrein protein sequence, research by Sidarovich and Fink³³ Sidarovich and Fink
Sidarovich V, Fink E. The 3'-terminal 13-bp segment of intron 1 is sufficient to promote transcriptional activity in the KLKB1 gene. Gene, 2009 demonstrated that the KLKB1 intron 1 harbors a 13-bp regulatory element sufficient to promote transcriptional activity and recruit alternative promoters. Intronic variants in this regulatory region plausibly alter the level of KLKB1 mRNA produced in the liver and kidney, where the gene is predominantly expressed. The T allele at rs4253238 is associated with increased plasma kallikrein enzymatic activity.

Active plasma kallikrein has multiple substrates. Its classical function is to cleave high-molecular-weight kininogen⁴⁴ high-molecular-weight kininogen
the plasma protein that serves as the precursor to bradykinin, the vasodilatory, pro-inflammatory peptide central to ACE-inhibitor activity to release bradykinin. Beyond bradykinin, plasma kallikrein also cleaves precursors of endothelin-1 (ET-1) and adrenomedullin (ADM)⁵⁵ endothelin-1 (ET-1) and adrenomedullin (ADM)
ET-1 is a potent vasoconstrictor and predictor of cardiac death; ADM is a vasodilatory peptide elevated in heart failure into smaller peptide fragments. The measurement of CT-pro-endothelin-1 and MR-pro-adrenomedullin as circulating surrogates of ET-1 and ADM activity means that higher plasma kallikrein activity registers as elevated levels of these cardiovascular biomarkers.

The Evidence

The primary cardiovascular evidence comes from a large genome-wide association study of plasma CT-proET-1 and MR-proADM⁶⁶ genome-wide association study of plasma CT-proET-1 and MR-proADM
Verweij N et al. Genome-wide association study on plasma levels of midregional-proadrenomedullin and C-terminal-pro-endothelin-1. Hypertension, 2013 conducted in 3,444 discovery participants with replication in 3,230 additional European participants. Minor variants in KLKB1, including rs4253238, showed genome-wide significant associations with both MR-proADM (P=4.46×10⁻⁵²) and CT-proET-1 (P=1.23×10⁻¹²²). The researchers demonstrated mechanistically that purified plasma kallikrein can directly cleave both ADM and ET-1 precursor proteins into multiple smaller peptides, providing a biochemical explanation for the genetic association. Elevated CT-proET-1 and MR-proADM are established predictors of cardiac death and heart failure.

An independent genome-wide protein QTL study⁷⁷ genome-wide protein QTL study
Portelli MA et al. Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels. FASEB J, 2014 in 584 control/asthma participants and 219 COPD participants confirmed that the rs4253238 T:T genotype is directly associated with elevated plasma kallikrein enzymatic activity (combined P=5.04×10⁻¹²). Higher kallikrein activity was inversely correlated with circulating soluble uPAR levels, a receptor involved in vascular repair and inflammatory signaling.

The cardiovascular implications of altered plasma kallikrein activity were clarified by Stavrou et al.⁸⁸ Stavrou et al.
Stavrou EX et al. Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. Blood, 2015 who found that Klkb1-knockout mice show significantly delayed arterial thrombosis — the paradoxical protection arising from upregulation of the Mas receptor/prostacyclin axis and suppression of tissue factor. This study establishes plasma kallikrein as a net pro-thrombotic driver in the contact activation pathway; higher KLKB1 activity from the T allele thus associates with a modestly more pro-thrombotic vascular environment.

A review by Feener et al.⁹⁹ Feener et al.
Feener EP et al. Role of plasma kallikrein in diabetes and metabolism. Thromb Haemost, 2013 confirmed that common KLKB1 variants associate with blood metabolite levels, hypertension, and coagulation in population studies. Notably, the Rohmann 2019¹⁰¹⁰ Rohmann 2019
Rohmann JL et al. Genetic determinants of activity and antigen levels of contact system factors. J Thromb Haemost, 2019 GWAS found that contact activation variants were not significantly associated with myocardial infarction or stroke risk in women under 50, suggesting that the kallikrein-modulating effect of rs4253238 primarily manifests as altered biomarker levels rather than directly elevated event risk in isolation.

Practical Implications

The T allele elevates plasma kallikrein activity, which simultaneously elevates bradykinin (vasodilatory, cardioprotective) and increases cleavage of ET-1 precursors (elevating circulating CT-proET-1, a cardiac stress marker). The net clinical significance of this variant is not fully resolved — elevated bradykinin is protective in ischemic conditioning and may enhance ACE-inhibitor effects, while elevated CT-proET-1 signals greater endothelin pathway activity associated with cardiac load. Heterozygotes (CT) have intermediate kallikrein activity levels. Monitoring cardiovascular biomarkers (particularly high-sensitivity CRP, BNP/NT-proBNP, and if available CT-proET-1) provides the most actionable information for TT genotype carriers.

Interactions

rs4253238 (KLKB1) has a documented epistatic interaction with rs2731672 (F12, coagulation factor XII), the upstream activating protease in the contact system. Together, KLKB1 and F12 variants modulate the full throughput of the contact activation cascade — bradykinin generation, complement activation, and endothelin surrogate levels. The Verweij 2013 GWAS identified both rs4253238 (KLKB1) and rs2731672 (F12) as independent contributors to CT-proET-1 and MR-proADM plasma levels, consistent with additive effects along the same proteolytic axis. The Gianni 2017 study (PMID 29130992) also demonstrated that combined KLKB1-428 and F12-46C/T variants produce an 8.8-year delay in hereditary angioedema onset — confirming meaningful gene-gene epistasis between these two contact system proteins. Carriers of risk genotypes in both rs4253238 (KLKB1) and rs2731672 (F12) likely have the highest contact-activation throughput and greatest endothelin/adrenomedullin surrogate elevation.

The UMOD gene encodes uromodulin¹¹ uromodulin
Also called Tamm-Horsfall protein, uromodulin is the most abundant protein in normal human urine, produced exclusively by cells lining the thick ascending limb of the loop of Henle, a protein with a paradoxical dual role in kidney health. Uromodulin forms protective filaments in urine that trap bacteria and prevent urinary tract infections²² trap bacteria and prevent urinary tract infections
Uromodulin polymerizes into filaments that bind type 1 fimbriae on uropathogenic E. coli, blocking their attachment to the bladder wall, but it also activates sodium reabsorption in the kidney, driving up blood pressure. The rs4293393 variant sits in the UMOD promoter region³³ UMOD promoter region
Located 550 base pairs upstream of the transcription start site, within a glucocorticoid response element, where it controls how much uromodulin your kidneys produce — and more is not always better.

The Mechanism

The rs4293393 risk allele (A on the plus strand, reported as T in the medical literature since UMOD is on the minus strand) sits within a glucocorticoid response element⁴⁴ glucocorticoid response element
A DNA sequence where glucocorticoid receptor proteins bind to regulate gene transcription in the UMOD promoter. The risk allele approximately doubles promoter activity⁵⁵ doubles promoter activity
Luciferase reporter assays showed ~2-fold higher transcription with the risk allele across multiple kidney cell lines compared to the protective G allele, leading to higher uromodulin production. This excess uromodulin activates the NKCC2 sodium-potassium-chloride cotransporter⁶⁶ NKCC2 sodium-potassium-chloride cotransporter
The key sodium reabsorption channel in the thick ascending limb of the loop of Henle, activated via SPAK/OSR1 kinase signaling in the thick ascending limb of the loop of Henle, increasing sodium reabsorption and driving salt-sensitive hypertension. The same mechanism causes progressive kidney damage through sustained hemodynamic stress on nephrons.

The Evidence

The UMOD promoter locus is one of the strongest and most replicated GWAS signals for kidney function. A landmark Icelandic study⁷⁷ landmark Icelandic study
Gudbjartsson et al. PLoS Genetics 2010 — 3,203 CKD cases and 38,782 controls from deCODE found the risk allele conferred CKD susceptibility with OR 1.25 (P = 4.1 x 10⁻¹⁰), while paradoxically protecting against kidney stones (OR 0.88, P = 5.7 x 10⁻⁵). A critical finding was that the effect on serum creatinine is strongly age-dependent⁸⁸ strongly age-dependent
Negligible before age 50 but accelerating rapidly after, at ~0.09 μmol/L per allele per year — negligible before age 50 but increasing sharply thereafter, particularly in the presence of comorbidities like diabetes and hypertension.

The Framingham Heart Study⁹⁹ Framingham Heart Study
Köttgen et al. JASN 2010 — 200 FHS participants with uromodulin measurements and genotyping demonstrated a striking dose-response: urinary uromodulin concentrations were 5.5 μg/mL with two risk alleles versus just 1.5 μg/mL with two protective alleles, and elevated uromodulin preceded incident CKD (OR 1.72 per SD increase).

The largest study to date, a PheWAS in 648,593 veterans¹⁰¹⁰ PheWAS in 648,593 veterans
Hung et al. Kidney Int Rep 2022 — Million Veteran Program multiethnic biobank from the Million Veteran Program, confirmed CKD risk (OR 1.22), hypertension (OR 1.03), gout (OR 1.04), and demonstrated protective effects against UTIs (OR 0.94) and kidney stones (OR 0.85) — all in non-Hispanic White participants. Notably, these associations were absent or attenuated in Black participants.

Practical Implications

The UMOD risk allele is extraordinarily common — carried by approximately 80% of people of European and African ancestry and over 90% in East Asian populations. This high frequency is maintained by pathogen-driven natural selection¹¹¹¹ pathogen-driven natural selection
Olden et al. JASN 2016 — analysis of 156 worldwide populations showed UMOD risk allele frequency correlates with bacterial diversity and UTI-causing pathogen prevalence: the same allele that increases CKD risk also protects against urinary tract infections, a major cause of morbidity throughout human evolution. The protective allele was found in Neanderthal and Denisovan genomes but has been selected against in modern humans, likely because UTI protection was more immediately advantageous than avoiding late-onset kidney disease.

The strongly age-dependent effect means this variant matters most after age 50, especially in the context of other metabolic risk factors. The mechanism through NKCC2 activation makes this a genuinely salt-sensitive form of hypertension — carriers may respond specifically to loop diuretics¹²¹² loop diuretics
Studies showed the loop diuretic furosemide produced greater blood pressure reduction and natriuresis in homozygous risk carriers compared to non-carriers and sodium restriction.

Interactions

rs4293393 is in near-perfect linkage disequilibrium¹³¹³ near-perfect linkage disequilibrium
r² = 0.95–1.0 in HapMap CEU populations with rs12917707, meaning these two SNPs are effectively the same signal — a person's genotype at one nearly always predicts their genotype at the other. Both tag the same UMOD promoter haplotype. rs13333226 is another SNP in the same LD block with concordant effects on uromodulin expression and CKD risk.

The UMOD mechanism intersects with other kidney function pathways. Variants in SLC22A2 (organic cation transporter, relevant to metformin clearance), SLC34A1 (phosphate transport), and APOL1 (African-ancestry CKD risk) affect kidney function through independent mechanisms and could compound CKD risk when present alongside the UMOD risk allele.

Your genome is copied and transmitted to the next generation in sperm and eggs. Every round of cell division during gametogenesis introduces errors — and the mismatch repair (MMR) system¹¹ mismatch repair (MMR) system
the cellular machinery that corrects base mismatches and insertion/deletion errors after DNA replication catches most of them before they become permanent. MSH2 is the central scaffold of this system: it forms the MutSα heterodimer with MSH6 to detect mismatches, and the MutSβ heterodimer with MSH3 to handle larger insertion/deletion loops. The Gly322Asp variant sits in the connector domain of MSH2, a structural region that mediates the critical handoff between mismatch recognition and downstream repair signaling through MLH1.

The Mechanism

Glycine at position 322 is part of a conserved loop in MSH2's connector domain (domain II), which serves as the physical interface with MutL homologs²² MutL homologs
the MLH1-PMS2 complex that executes strand excision after mismatch recognition. Replacing glycine — a structurally flexible amino acid — with aspartate introduces a bulkier, charged side chain that subtly alters connector domain geometry. Functional studies give mixed results: an in vitro MMR assay using human nuclear extracts found statistically significant reduction in repair efficiency (~10% of wild-type³³ statistically significant reduction in repair efficiency (~10% of wild-type
Andres et al. 2014, PMC4273566), while an earlier study using purified recombinant protein found no impairment in MSH2-MSH6 complex formation, mismatch binding, or repair activity (Kariola et al. 2008)⁴⁴ (Kariola et al. 2008). The discrepancy likely reflects assay sensitivity: purification steps may exclude structurally damaged heterodimers, making cell extract assays more representative of in vivo conditions.

The Evidence

The most definitive evidence comes from a genome-scale study in Iceland. Kristmundsdottir et al. (2023, Nature Communications)⁵⁵ Kristmundsdottir et al. (2023, Nature Communications)
Sequence variants affecting the genome-wide rate of germline microsatellite mutations analyzed whole-genome sequences from 6,084 Icelandic parent-offspring trios and identified rs4987188[A] as a variant that significantly increases transmitted microsatellite de novo mutations: +13.1 mutations in the paternal lineage and +7.8 in the maternal lineage per offspring per generation (P = 3.6×10⁻¹⁰, effect size 0.37 standard deviations). At a baseline of ~64 microsatellite de novo mutations per generation, the A allele represents a ~12–20% increase in germline microsatellite instability, carried symmetrically through both sperm and eggs. Crucially, the similar effect in both sexes indicates that germ cells from both parents are subject to the same MSH2-dependent sequence fidelity process.

ClinVar classification is Benign for Lynch syndrome (expert panel reviewed, InSiGHT September 2013, VCV000001762), based on allele frequency exceeding 1% in the population, lack of disease segregation in Lynch families, and the absence of clear mismatch repair deficiency on standard assays. The germline mutation-rate effect is a distinct phenotype from Lynch syndrome: it does not cause microsatellite instability in tumor DNA, but does modestly increase the per-generation mutation load passed to children.

Smaller case-control studies have explored cancer associations with inconsistent results. A Polish series found MSH2 Gly322Asp associated with colorectal cancer recurrence (p=0.001)⁶⁶ MSH2 Gly322Asp associated with colorectal cancer recurrence (p=0.001)
Plawski et al. 2017 and a separate Polish cohort reported a protective association with triple-negative breast cancer for the Asp allele, though these studies are small (n ≈ 70–144) and have not been replicated in larger populations.

Practical Actions

For AG heterozygotes, the effect on germline mutation rate is modest — a ~10–15% above-baseline increase in transmitted microsatellite mutations. No specific medical intervention is currently indicated. The finding is most relevant for genetic counseling context in families with unexplained de novo diseases or autism spectrum conditions (where microsatellite instability is one contributor to de novo mutation burden), and for couples undergoing IVF where preimplantation genetic testing for aneuploidy (PGT-A) is already planned.

For AA homozygotes (extremely rare, <0.03% globally), the expected additive effect would be roughly double the heterozygote increase in germline mutation rate. Given how rarely this genotype occurs, robust clinical data specific to AA homozygosity are unavailable; the recommendations remain an extrapolation from the per-allele dosage effect.

Interactions

MSH2 works in obligate heterodimer complexes, so the biological output of Gly322Asp depends on the functional state of its partners — particularly MSH6 (rs2303426 in the MSH2-MSH6 interface region) and MLH1 (rs1799977, already in the GeneOps database). The variant in MLH1 (rs1799977, Ile219Val) sits in the MLH1 ATPase domain that docks with MSH2's connector domain; if a person carries both rs4987188 (MSH2 G322D) and rs1799977 (MLH1 I219V), the connector-domain interface is disrupted from both ends. A compound action covering this combination is worth investigating if familial MMR deficiency studies show additive effects.

EXO1 (rs72755295 and rs1635501 in the GeneOps database) acts downstream of MSH2 in the excision step; MSH2-EXO1 pathway efficiency is relevant to meiotic crossover fidelity. Variants in EXO1 combined with MSH2 G322D could compound the germline mutation-rate phenotype through reduced excision capacity after mismatch recognition.

Your liver cells constantly remodel the fatty acid tails of membrane phospholipids, swapping in and out different acyl chains to maintain proper membrane composition and signaling. The MBOAT7 gene¹¹ MBOAT7 gene
membrane-bound O-acyltransferase domain-containing 7, also known as LPIAT1 (lysophosphatidylinositol acyltransferase 1) encodes the enzyme responsible for one specific and critical step in this process: re-acylating lysophosphatidylinositol (lyso-PI)²² lysophosphatidylinositol (lyso-PI)
a phospholipid stripped of its sn-2 fatty acid tail with arachidonoyl-CoA to produce PI(18:0/20:4), the dominant phosphatidylinositol species in hepatocyte membranes. The rs641738 variant reduces MBOAT7 expression in the liver, depleting this key phospholipid and tipping the balance toward hepatic fat accumulation and inflammation.

The Mechanism

MBOAT7 operates within the Lands cycle³³ Lands cycle
a phospholipid remodeling pathway where phospholipase A2 cleaves the sn-2 fatty acid from a phospholipid, creating a lysophospholipid, and an acyltransferase re-esterifies it with a new fatty acid. What makes MBOAT7 unique among the MBOAT family is its exquisite substrate selectivity: it preferentially esterifies arachidonoyl-CoA (C20:4, an omega-6 fatty acid) into the sn-2 position of lyso-PI. This selectivity means MBOAT7 is the primary enzyme determining how much arachidonic acid ends up in phosphatidylinositol pools.

The rs641738 T allele sits in the regulatory region between MBOAT7 and TMC4 on chromosome 19. It does not change the MBOAT7 protein sequence, but it reduces MBOAT7 mRNA and protein expression in hepatocytes. Lipidomic profiling of human liver biopsies shows that T allele carriers have markedly reduced PI species containing arachidonoyl chains — primarily PI(18:0/20:4) — and elevated levels of the precursor 18:0-lyso-PI and 18:1-lyso-PI⁴⁴ Lipidomic profiling of human liver biopsies shows that T allele carriers have markedly reduced PI species containing arachidonoyl chains — primarily PI(18:0/20:4) — and elevated levels of the precursor 18:0-lyso-PI and 18:1-lyso-PI
Luukkonen et al. The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. J Hepatol, 2016. The functional consequence is a deficit in arachidonoyl-PI, which disrupts membrane signaling, lipid droplet dynamics, and inflammatory tone in the liver.

When MBOAT7 activity falls, the accumulation of lyso-PI and the depletion of mature PI species promote de novo lipogenesis and triglyceride accumulation in hepatocytes. MBOAT7 also appears to shape the availability of arachidonic acid for downstream eicosanoid production, linking phospholipid remodeling to inflammatory signaling in Kupffer cells and hepatic stellate cells.

The Evidence

The variant was first identified as a NAFLD risk locus in the landmark study by Mancina et al.⁵⁵ landmark study by Mancina et al.
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology, 2016, which examined 3,854 participants in the multi-ethnic Dallas Heart Study and 1,149 European liver biopsy patients. Each T allele increased risk of hepatic steatosis (OR 1.42 in the biopsy cohort), NASH (OR 1.18), and significant fibrosis (OR 1.30). In European Americans specifically, the per-allele OR for steatosis was 1.37.

The definitive evidence came from a meta-analysis of 42 studies encompassing over one million participants (9,688 with liver biopsies)⁶⁶ meta-analysis of 42 studies encompassing over one million participants (9,688 with liver biopsies)
Teo et al. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. J Hepatol, 2021. This analysis confirmed that the T allele increases risk of NAFLD diagnosis (OR 1.17), advanced fibrosis under a recessive model (OR 1.22), and elevated ALT, while lowering serum triglycerides. Crucially, the association was robust in European adults but was not replicated in children or in non-European populations, suggesting the effect may be modulated by environmental or developmental factors.

Beyond NAFLD, rs641738 T increases risk of liver inflammation and accelerated fibrosis progression in chronic hepatitis C⁷⁷ rs641738 T increases risk of liver inflammation and accelerated fibrosis progression in chronic hepatitis C
Thabet et al. MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nat Commun, 2016 (n=2,051), and increases hepatocellular carcinoma risk in non-cirrhotic patients with liver disease⁸⁸ increases hepatocellular carcinoma risk in non-cirrhotic patients with liver disease
Donati et al. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Sci Rep, 2017 (OR 2.10 in combined non-cirrhotic cohort).

The effect size of rs641738 is modest compared to PNPLA3 rs738409 (the strongest NAFLD risk variant), but it acts through an independent pathway — phospholipid remodeling rather than triglyceride hydrolysis — making it a complementary risk factor with additive effects when combined with PNPLA3 and TM6SF2 risk alleles.

Practical Actions

For T allele carriers, the key insight is that your liver's phosphatidylinositol remodeling is compromised. MBOAT7 preferentially incorporates arachidonic acid (an omega-6 PUFA) into PI, and when this process is impaired, the ratio of omega-6 to omega-3 fatty acids in hepatic membranes shifts. Dietary strategies that increase EPA and DHA intake can partially compensate by providing alternative substrates for membrane phospholipid composition and by dampening the inflammatory signaling that MBOAT7 deficiency amplifies.

Monitoring liver enzymes (ALT, GGT) is particularly relevant because the T allele independently raises ALT. A mildly elevated ALT in a TT homozygote may reflect the genetic predisposition rather than acute liver injury, but it also signals that the liver is under more metabolic stress than the same ALT value would indicate in a CC individual.

Interactions

MBOAT7 rs641738 interacts additively with PNPLA3 rs738409 and TM6SF2 rs58542926. In a multicenter biopsy-based study of 515 NAFLD patients⁹⁹ multicenter biopsy-based study of 515 NAFLD patients
Krawczyk et al. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity. J Lipid Res, 2017, the three variants contributed through distinct mechanisms: PNPLA3 drove both steatosis and fibrosis, TM6SF2 primarily steatosis, and MBOAT7 selectively fibrosis (OR 1.77 in multivariate analysis). Increasing numbers of risk alleles across all three loci correlated with progressively higher liver enzymes.

The MTARC1 protective variant (rs2642438) operates in a complementary pathway — while MBOAT7 deficiency impairs phospholipid remodeling, MTARC1 loss-of-function enhances hepatic fat oxidation. Carriers of MBOAT7 risk alleles who also carry MTARC1 protective alleles may experience partial offset of their fibrosis risk, though this specific interaction has not yet been directly quantified.

HSD17B13 rs72613567 (a protective splice variant) also interacts with MBOAT7 risk through complementary mechanisms: HSD17B13 loss-of-function reduces hepatic lipid droplet toxicity while MBOAT7 deficiency increases it, making the presence or absence of HSD17B13 protection relevant for MBOAT7 risk carriers.

Chromosome 8q24 is the most frequently implicated region in cancer genome-wide association studies, yet it contains no protein-coding genes for hundreds of kilobases. The variant rs6983267 sits in an intergenic desert roughly 335 kilobases upstream of MYC¹¹ MYC
MYC is one of the most potent human oncogenes; its protein product drives cell proliferation, and it is overexpressed in the majority of human cancers, one of the most important oncogenes in human biology. Despite its distance from any gene, this single nucleotide change has a direct and well-characterized mechanism linking it to cancer risk.

The Mechanism

The region surrounding rs6983267 functions as a transcriptional enhancer — a stretch of DNA that boosts the expression of distant genes through physical looping of the chromosome. Pomerantz et al.²² Pomerantz et al.
Pomerantz MM et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet, 2009 used chromosome conformation capture (3C) to demonstrate that this enhancer physically contacts the MYC promoter across 335 kb of intervening DNA. The G risk allele creates a stronger binding site for TCF7L2³³ TCF7L2
Also known as TCF4; a transcription factor in the Wnt signaling pathway that, when activated, drives expression of growth-promoting genes including MYC, a key transcription factor in the Wnt signaling pathway⁴⁴ Wnt signaling pathway
The Wnt pathway controls cell proliferation, polarity, and fate during development; its aberrant activation is a hallmark of colorectal cancer.

Tuupanen et al.⁵⁵ Tuupanen et al.
Tuupanen S et al. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet, 2009 confirmed this mechanism using reporter assays and chromatin immunoprecipitation: the G allele binds TCF7L2 more strongly both in vitro and in vivo, effectively amplifying Wnt-driven MYC expression. In the most striking functional validation, Sur et al.⁶⁶ Sur et al.
Sur IK et al. Mice lacking a Myc enhancer that includes human SNP rs6983267 are resistant to intestinal tumors. Science, 2012 deleted this enhancer region in mice and found they were markedly resistant to intestinal tumors driven by APC mutations — the same pathway responsible for most human colorectal cancers.

The Evidence

rs6983267 is one of the most replicated cancer GWAS findings in the literature. The initial identification came from two independent 2007 studies: Tomlinson et al.⁷⁷ Tomlinson et al.
Tomlinson I et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet, 2007 found the G allele increased colorectal cancer risk with an OR of 1.27 for heterozygotes and 1.47 for GG homozygotes in a large British cohort. Simultaneously, Haiman et al.⁸⁸ Haiman et al.
Haiman CA et al. A common genetic risk factor for colorectal and prostate cancer. Nat Genet, 2007 showed the same variant conferred risk for both colorectal and prostate cancer with an OR of 1.22 per allele.

A comprehensive meta-analysis of 78 studies⁹⁹ comprehensive meta-analysis of 78 studies
Zhu M et al. Association between 8q24 rs6983267 polymorphism and cancer susceptibility: a meta-analysis involving 170,737 subjects. Oncotarget, 2017 pooling 73,996 cancer cases and 96,741 controls confirmed statistically robust associations across multiple cancer types. The GG genotype conferred an OR of 1.31 compared to TT, while per-allele risk was 1.14. The association was strongest for colorectal cancer in Caucasians and prostate cancer in both Caucasians and Asians.

A critical point: this is a very common variant with a small per-allele effect. The G allele is actually the major allele in most populations (frequency ~50-58%), meaning the majority of people carry at least one copy. The absolute risk increase per individual is modest — this is not a rare, high-penetrance mutation like BRCA1. Its public health significance comes from its extreme prevalence.

Practical Implications

The actionability of rs6983267 centers on cancer screening adherence rather than lifestyle interventions. Because the Wnt/MYC mechanism directly promotes colorectal neoplasia through adenoma formation, colonoscopy screening is the most evidence-based response — it detects and removes the precancerous adenomas that this variant promotes. For prostate cancer, the variant contributes to a genetic risk profile that informs PSA screening discussions.

An intriguing pharmacogenomic interaction exists with aspirin: Nan et al.¹⁰¹⁰ Nan et al.
Nan H et al. Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. JNCI, 2013 found that aspirin's colorectal cancer protection was confined to individuals carrying the protective T allele, while those homozygous for the risk G allele derived less benefit. This may relate to the G allele's stronger Wnt activation partially overriding aspirin's anti-Wnt effects.

Interactions

rs6983267 resides in the same cancer risk region as other 8q24 variants that influence different cancer types through distinct mechanisms. Its colorectal cancer association intersects with the mismatch repair pathway: individuals who carry both the rs6983267 GG genotype and variants in mismatch repair genes such as MLH1 (rs1800734) or APC pathway components (rs1801155/APC I1307K) may face compounded colorectal cancer susceptibility. The Wnt pathway activation from rs6983267 combined with impaired DNA repair from mismatch repair variants would create a dual vulnerability — both increased cell proliferation and reduced error correction. This interaction is biologically plausible given that APC mutations and MYC overexpression are sequential events in the adenoma-carcinoma progression model.

The KCNK9 gene encodes TASK3, a two-pore domain background potassium channel¹¹ two-pore domain background potassium channel
K2P channel: always-open K⁺ leak channels that set the resting membrane potential of excitable and secretory cells that is highly expressed in the adrenal zona glomerulosa — the thin outer layer of the adrenal cortex responsible for producing aldosterone. Aldosterone is the steroid hormone that tells the kidneys to retain sodium and water, raising blood volume and therefore blood pressure. When TASK3 channel activity is reduced, zona glomerulosa cells depolarize, increasing calcium influx and stimulating excess aldosterone synthesis. rs6997709 sits approximately 433 kilobases upstream of KCNK9 in an intergenic region that may influence KCNK9 expression through long-range regulatory elements, and its T allele was flagged as a suggestive hypertension signal in the landmark 2007 Wellcome Trust Case Control Consortium (WTCCC) genome-wide association study.

The Mechanism

TASK3 (KCNK9) and its close relative TASK1 (KCNK3) together produce the background K⁺ conductance that sets the resting membrane potential of adrenal glomerulosa cells. Bandulik et al. 2010²² Bandulik et al. 2010
Bandulik S et al. TASK1 and TASK3 potassium channels: determinants of aldosterone secretion and adrenocortical zonation. Horm Metab Res 2010 showed that these channels are molecular targets of angiotensin II signalling: when angiotensin II binds its receptor, it closes these channels, depolarizes the membrane, and opens voltage-gated calcium channels to drive aldosterone secretion. Genetically reducing this channel tone — as in Kcnk9-knockout mice — produces autonomous aldosterone excess and elevated blood pressure even without elevated renin.

rs6997709 is an intergenic regulatory variant; it does not change the TASK3 protein itself. Its position ~433 kb upstream of KCNK9 places it in a region that may harbour enhancer elements with long-range chromatin contacts to the KCNK9 promoter. The T allele may reduce TASK3 expression, tilting the zona glomerulosa toward a more depolarized resting state and enhanced aldosterone responsiveness.

The Evidence

The WTCCC 2007 genome-wide association study³³ WTCCC 2007 genome-wide association study
Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007 identified rs6997709 as a suggestive hypertension signal in a British population (n ~2,000 hypertensive cases, ~3,000 controls). A Korean replication study (Hong et al. 2009)⁴⁴ Korean replication study (Hong et al. 2009)
Hong KW et al. Replication of the WTCCC genome-wide association study on essential hypertension in a Korean population. Hypertens Res 2009 found rs6997709 associated with systolic blood pressure in a continuous trait analysis, though it did not reach case-control significance, consistent with a modest additive effect on BP rather than a binary hypertension switch.

Mechanistic support comes from a study by Jung et al. 2012⁵⁵ Jung et al. 2012
Jung J et al. Variations in the potassium channel genes KCNK3 and KCNK9 in relation to blood pressure and aldosterone production. J Clin Endocrinol Metab 2012 that examined 74 KCNK9 SNPs in 795 participants: multiple KCNK9 variants associated with systolic blood pressure in African Americans and with aldosterone production indices in both European and African Americans, placing the KCNK9 locus within the aldosterone pathway that links potassium channel genetics to blood pressure.

A 2025 nutrigenetics scoping review Holzbach et al. 2025⁶⁶ Holzbach et al. 2025
Holzbach LC et al. Nutrigenetics and Nutritional Strategies in Systemic Arterial Hypertension. Nutr Rev 2025 identified rs6997709 among 13 SNPs with documented interactions with dietary sodium intake and blood pressure, consistent with an aldosterone-mediated salt-sensitivity mechanism.

The evidence level is moderate: the original GWAS signal was suggestive rather than genome-wide significant, and the biological mechanism (regulatory effect on KCNK9 expression) has not yet been confirmed by eQTL studies at this specific locus.

Practical Actions

For T-allele carriers, the most relevant lever is dietary sodium. If the KCNK9 locus reduces aldosterone-suppressing channel tone, then high sodium intake may be more pressor for T carriers than for GG individuals. Specifically:

• Restrict dietary sodium to below 2,000 mg/day (roughly 5 g salt), a threshold that clinical guidelines already recommend for hypertension management but that carries extra weight here given the gene-sodium interaction evidence.
• Monitor blood pressure proactively — home blood pressure monitoring provides higher-resolution data than clinic visits and can detect masked or white-coat hypertension.
• Monitor aldosterone-to-renin ratio (ARR) if blood pressure is consistently elevated despite dietary intervention, as the mechanistic model predicts aldosterone-driven low-renin hypertension rather than classical renin-dependent hypertension.

Interactions

The strongest compound interaction partner is GNB3 rs5443, which also showed sodium-interaction in the same scoping review and is a well-established modulator of blood pressure in salt-sensitive populations. ACE rs4646994 and NOS3 rs2070744 interact with the same aldosterone-renin-angiotensin axis; individuals carrying risk variants at multiple loci in this pathway may have additive hypertension susceptibility.

Within the KCNK9 gene itself, rs888345 is the KCNK9 intronic variant most strongly associated with blood pressure in African Americans and with aldosterone production indices in both Europeans and African Americans; it may be in partial linkage disequilibrium with rs6997709 in some populations.

The Thr105Ile ¹¹ Threonine to isoleucine at position 105 variant (rs11558538) is a well-characterized missense mutation in the HNMT gene that replaces threonine with isoleucine at position 105. Unlike the 3'UTR variant that affects how much enzyme is made, this variant changes the enzyme's structural stability and catalytic efficiency.

The Mechanism

Position 105 lies near the active site of HNMT where SAM and histamine bind. The isoleucine substitution (T allele) destabilizes the protein, leading to faster degradation and lower steady-state enzyme levels in cells. Studies using recombinant HNMT ²² Recombinant protein is produced in laboratory cells to study enzyme properties in isolation from other cellular factors have shown that the Ile105 variant has reduced thermal stability and lower catalytic activity compared to the wild-type Thr105 enzyme. The threonine residue creates a more accessible conformation of substrate binding residues than the isoleucine variant, resulting in higher enzymatic activity.

The Evidence

Preuss et al. (1998)³³ Preuss et al. (1998)
Preuss CV et al. Human Histamine N-Methyltransferase Pharmacogenetics: Common Genetic Polymorphisms That Alter Activity. Mol Pharmacol, 1998 demonstrated that individuals with the TT genotype had significantly lower HNMT enzyme activity in red blood cells. Subsequent studies confirmed that this variant is associated with increased susceptibility to allergic diseases, asthma, and histamine-related symptoms, particularly in European populations. The variant is relatively uncommon in homozygous form (about 2% of Europeans), but heterozygous carriers (about 18%) may experience subtle effects, particularly when combined with other histamine pathway variants. Interestingly, meta-analyses⁴⁴ meta-analyses
Thr105Ile and Parkinson disease meta-analysis have suggested that the Ile105 variant may be associated with reduced risk of Parkinson disease, possibly through altered brain histamine levels.

Brain Histamine

HNMT is the only enzyme that degrades histamine in the brain, where histamine acts as a neurotransmitter ⁵⁵ Brain histamine is released by tuberomammillary neurons in the hypothalamus and helps regulate the sleep-wake cycle involved in wakefulness, appetite, and cognition. Reduced HNMT activity can alter brain histamine signaling, which may partly explain why some individuals with HNMT variants report sleep disturbances, anxiety, or cognitive effects in response to histamine triggers.

Practical Considerations

If you carry the T allele, supporting your methylation pathway (which supplies SAM for HNMT) becomes even more important, since your enzyme is already working at reduced capacity. Combined with DAO variants, this can create a significant histamine clearance deficit that benefits from both dietary management and methylation support.

Your pancreatic beta cells have a sophisticated system for sensing blood glucose and responding with precisely calibrated insulin release. ADCY5 (adenylate cyclase 5) sits at a critical junction in this signaling chain: it converts a glucose-triggered metabolic signal into cAMP¹¹ cAMP
cyclic AMP — a second messenger molecule that amplifies signals inside cells, in this case activating protein kinase A and Epac proteins to drive insulin granule fusion and secretion, which then drives insulin granule fusion with the cell membrane and release into the bloodstream. The rs11708067 variant near this gene affects how much ADCY5 your islet cells produce — and when that production is reduced, the glucose-to-insulin signal becomes muffled.

The Mechanism

rs11708067 sits in intron 3 of the ADCY5 gene, within what turns out to be a key regulatory enhancer active specifically in pancreatic islets. The A risk allele disrupts this enhancer. Functional studies by Roman and colleagues²² Roman and colleagues
Roman TS et al. A Type 2 Diabetes-Associated Functional Regulatory Variant in a Pancreatic Islet Enhancer at the ADCY5 Locus. Diabetes, 2017 showed that the A allele carries fewer active chromatin marks (H3K27ac) in human islets, has lower transcriptional activity in reporter assays, and increased nuclear protein binding — all signs of a disrupted enhancer. When the equivalent enhancer region was deleted in a beta-cell line, ADCY5 expression fell by 64% and insulin secretion dropped by 39%.

The consequence is selective: Hodson and colleagues³³ Hodson and colleagues
Hodson DJ et al. ADCY5 Couples Glucose to Insulin Secretion in Human Islets. Diabetes, 2014 demonstrated that ADCY5 is specifically required for translating elevated glucose concentrations into cAMP production. When ADCY5 is silenced, glucose-stimulated cAMP generation falls nearly threefold and insulin secretion is substantially impaired — but GLP-1-stimulated secretion remains intact because GLP-1 activates other adenylyl cyclase isoforms. Risk allele carriers show approximately twofold lower ADCY5 mRNA expression in islets, particularly in younger male AA carriers. A secondary defect has also been documented: Wagner and colleagues⁴⁴ Wagner and colleagues
Wagner R et al. Glucose-raising genetic variants in MADD and ADCY5 impair conversion of proinsulin to insulin. PLoS One, 2011 found that A allele carriers show impaired proinsulin-to-insulin conversion, meaning beta cells produce proportionally more of the inactive precursor form.

The Evidence

The original discovery came from a landmark meta-analysis⁵⁵ landmark meta-analysis
Dupuis J et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet, 2010 of 21 genome-wide association studies in up to 46,186 non-diabetic participants with follow-up in an additional 76,558 individuals. rs11708067 emerged as one of nine newly discovered fasting glucose loci, with each A allele associated with a +0.027 mmol/L (0.49 mg/dL) increase in fasting glucose (p=7.1×10⁻²²) and OR 1.12 for type 2 diabetes (p=9.9×10⁻²¹). Crucially, the variant was associated with reduced HOMA-B (beta-cell function) but not HOMA-IR (insulin resistance), confirming the effect is specifically on insulin secretion capacity, not insulin sensitivity.

Replication across ethnicities strengthens the evidence. A South Asian study⁶⁶ South Asian study
Rees SD et al. Effects of 16 genetic variants on fasting glucose and type 2 diabetes in South Asians: ADCY5 and GLIS3 variants may predispose to type 2 diabetes. PLoS One, 2011 in 1,678 cases and 1,584 controls confirmed OR 1.23 (95% CI 1.09–1.39, p=9.1×10⁻⁴). Pathway studies in GWAS of early childhood glucose levels also found ADCY5 rs11708067 among the variants cumulatively raising plasma glucose by 0.053 mmol/L per risk allele from birth onward.

The developmental origin of this risk was confirmed by Aguilera-Venegas and colleagues⁷⁷ Aguilera-Venegas and colleagues
Aguilera-Venegas A et al. Association of diabetes-related variants in ADCY5 and CDKAL1 with neonatal insulin, C-peptide, and birth weight. Endocrine, 2021 who showed that healthy newborns carrying the A allele had lower cord blood insulin and C-peptide concentrations, independent of maternal glycemia — demonstrating that reduced beta-cell insulin secretion capacity is present from the first moments of life.

Practical Actions

The ADCY5 glucose-signaling deficit operates specifically on the glucose→cAMP pathway. This creates a specific therapeutic relevance: because GLP-1 stimulated secretion is ADCY5-independent, GLP-1 receptor agonists (semaglutide, liraglutide) and DPP-4 inhibitors work through a preserved pathway in risk allele carriers. For AA homozygotes with elevated fasting glucose or impaired glucose tolerance, these incretin-based approaches may be particularly rational choices to discuss with a physician.

Dietary strategies that blunt the glucose spike — lower glycemic load meals, slower carbohydrate absorption — reduce the demand on the already-reduced ADCY5-mediated secretion capacity. Continuous glucose monitoring can reveal whether postprandial responses are adequate despite the secretion deficit. Given the proinsulin conversion defect, fasting proinsulin:insulin ratio can serve as a sensitive early marker of beta-cell stress in high-risk individuals.

Interactions

ADCY5 rs11708067 sits within a broader beta-cell function locus. The neighboring SNP rs2877716 (C allele) tags the same ADCY5 risk haplotype and is often genotyped in parallel studies. Co-carriage of rs11708067 risk alleles with SLC30A8 rs13266634 (zinc transporter 8) compounds beta-cell secretory dysfunction through independent mechanisms — ZnT8 affects insulin granule maturation while ADCY5 affects the upstream glucose-to-cAMP signal. Individuals carrying risk alleles at both loci show a convergent impairment in glucose-stimulated insulin release. TCF7L2 rs7903146 risk alleles further compound risk through a third mechanism involving incretin signaling and beta-cell development; population studies of early childhood glucose levels found ADCY5 and TCF7L2 variants among the most consistently replicated contributors to cumulative fasting glucose elevation.

The brain's immune cells — microglia — are its primary defence against accumulating amyloid-beta plaques, the toxic protein deposits that define Alzheimer's disease. To stay activated and effective, microglia rely on a molecular on-switch: the interleukin-1 signalling complex¹¹ interleukin-1 signalling complex
IL-1 cytokine signalling is critical for microglial reactivity, phagocytosis, and amyloid clearance, which includes the receptor accessory protein encoded by IL1RAP. The rs12053868 variant sits in an intron of this gene and — through regulatory changes in expression — subtly dampens the IL-1 signal that keeps microglia primed to clear amyloid. The result is measurable: a small but steady increase in the pace at which amyloid accumulates in the aging brain.

The Mechanism

IL1RAP encodes interleukin-1 receptor accessory protein²² interleukin-1 receptor accessory protein
IL1RAP forms an obligate co-receptor with IL1R1; neither unit can transduce IL-1β or IL-1α signals alone, an essential co-receptor subunit in the IL-1 signalling complex. When IL-1β binds, the IL1R1/IL1RAP heterodimer recruits MyD88 and triggers NF-κB, driving microglial reactivity, cytokine secretion, and phagocytic activity. rs12053868 lies in intron 3 at genomic position chr3:190,582,215 (GRCh38), on the plus strand. As an intronic regulatory variant it does not change the amino acid sequence of IL1RAP; instead it appears to act as an expression quantitative trait locus³³ expression quantitative trait locus
eQTL variants alter how much of a gene's protein is produced, not its structure that mildly reduces IL1RAP transcription in microglial and neuronal cells. Lower IL1RAP levels attenuate the IL-1 signalling cascade, reducing microglial responsiveness to early amyloid deposits — allowing plaques to accumulate before the immune response clears them. Separate mouse knockout data confirms that global loss of IL-1RAcP (the IL1RAP protein) reduces pathological tau phosphorylation⁴⁴ reduces pathological tau phosphorylation
pS202 and pT231 tau epitopes are reduced in LPS-challenged Il1rap knockout mice in inflammatory contexts, underscoring the pathway's centrality to both amyloid and tau pathology.

The Evidence

The primary evidence comes from a 2015 genome-wide association study⁵⁵ 2015 genome-wide association study
Ramanan et al., ADNI cohort, longitudinal 18F-florbetapir PET imaging over 2 years published in Brain that measured longitudinal amyloid accumulation — not just amyloid burden at a single point in time, but the rate at which amyloid built up year by year. In the ADNI cohort, each G allele copy was associated with a 0.8% per-year increase in cortical amyloid standardised uptake value ratio (SUVR), reaching genome-wide significance at p = 1.38×10⁻⁹. Critically, the association held independently of APOE ε4 — the strongest known Alzheimer's genetic risk factor — establishing IL1RAP as an orthogonal risk pathway. G allele carriers also showed greater temporal-cortex atrophy on MRI, accelerated progression from mild cognitive impairment to Alzheimer's disease, and lower cortical ¹¹C-PBR28 PET signal (a marker of microglial activation), directly connecting reduced IL1RAP activity to impaired microglial surveillance.

A 2019 Swedish study⁶⁶ 2019 Swedish study
Zettergren et al., N=3,446 cases/controls, N=1,400 for CSF biomarker analyses extended these findings to CSF biomarkers. While IL1RAP variants did not significantly alter lifetime Alzheimer's disease risk in this sample, they were significantly associated with elevated CSF total-tau and phospho-tau concentrations — biomarkers of neuronal injury and tangle formation that predict disease progression. The researchers concluded that IL1RAP genetic variation influences disease intensity (how aggressively neurodegeneration proceeds) rather than merely disease susceptibility, consistent with the amyloid accumulation rate finding.

The variant's minor-allele frequency differs substantially by ancestry: ~11% in Europeans, ~14% in East Asians, but only ~2% in Africans of African descent. This pattern means the G allele's impact on population-level Alzheimer's risk is most pronounced in East Asian and European communities.

Practical Actions

No drug or supplement has been proven to specifically reverse impaired IL1RAP signalling in humans. However, because the risk mechanism runs through microglial activation and neuroinflammation⁷⁷ microglial activation and neuroinflammation
Microglia clear amyloid by phagocytosis; dampened IL-1 signalling slows this process, strategies that support microglial function and reduce chronic neuroinflammation are the most plausible targets. Long-chain omega-3 fatty acids (EPA/DHA) modulate microglial phenotype toward a more phagocytic, amyloid-clearing state. Maintaining tight control of systemic inflammatory markers (hsCRP, IL-6) reduces the chronic inflammatory background that dysregulates the very IL-1 pathway this variant affects. Monitoring cognitive biomarkers (CSF tau/amyloid, or plasma p-tau181 where available) earlier than usual can establish baseline values and flag accelerated change.

Interactions

The effect of rs12053868 is independent of APOE ε4 (rs429358 / rs7412), meaning carriers of both face compounded risk through separate biological pathways: APOE ε4 reduces direct amyloid clearance efficiency, while rs12053868-G reduces the microglial surveillance that removes plaques at the source. The CLU rs11136000 (clusterin) variant acts in the same amyloid clearance biology; individuals carrying risk alleles in both genes may have meaningfully elevated cumulative risk. IL1RAP co-variation with rs9877502 — a separate IL1RAP locus associated with CSF tau — has not yet been formally modelled but represents a plausible intra-gene interaction worth monitoring as longitudinal cohort data mature.

About 19 kilobases downstream of IL2RA¹¹ IL2RA
the gene encoding CD25, the alpha chain of the high-affinity interleukin-2 receptor; CD25 is the defining surface marker of regulatory T cells (Tregs), rs12251307 sits in a region of open chromatin that functions as a long-range regulatory element for the locus. IL-2 signaling through CD25 is the central survival and activation signal for regulatory T cells²² regulatory T cells
Tregs are CD4+ immune cells that suppress excessive immune responses and maintain self-tolerance; CD25 gives Tregs preferential access to IL-2 at physiologically low concentrations. Variants across the IL2RA locus — including rs12251307 — collectively tune how much CD25 gets expressed on Treg surfaces, how sensitive those Tregs are to IL-2, and consequently how well the immune system is held in check. The T allele at this downstream position tags a configuration of the locus associated with mildly impaired immune regulation across multiple atopic and autoimmune phenotypes.

The Mechanism

rs12251307 is located on the plus strand of chromosome 10 at position 6,081,532 (GRCh38), classified as an intergenic variant with C as the GRCh38 reference allele and T as the alternate. The region around IL2RA contains multiple independent regulatory variants that together influence sIL-2RA shedding³³ sIL-2RA shedding
the alpha chain of the IL-2 receptor can be cleaved and released from the cell surface as soluble IL-2RA, which competes with membrane-bound receptors for available IL-2, thereby reducing the effective IL-2 signal reaching Tregs, intron-1 enhancer activity, and promoter accessibility. The T allele at rs12251307 acts as a tag for a broader haplotype across this ~20 kb region. Because IL2RA is on the minus strand, gene regulatory elements can extend well beyond the transcribed sequence into the 3' flank, and enhancer-promoter loops at this distance are well documented in immune loci. Mechanistically, T-allele haplotypes at this locus are associated with lower Treg STAT5 phosphorylation⁴⁴ Treg STAT5 phosphorylation
STAT5 is the intracellular signaling molecule activated when IL-2 binds to CD25-containing high-affinity receptor complexes; less pSTAT5 means weaker Treg activation even when IL-2 is present and reduced Treg suppressive capacity downstream of IL-2 stimulation.

The Evidence

The strongest signal comes from the 2023 Nature Communications atopic dermatitis GWAS meta-analysis. Budu-Aggrey et al. analyzed hundreds of thousands of individuals across European and multi-ancestry cohorts⁵⁵ Budu-Aggrey et al. analyzed hundreds of thousands of individuals across European and multi-ancestry cohorts, identifying rs12251307-T as a genome-wide significant risk allele for atopic dermatitis (OR 1.10, 95% CI 1.09–1.11; p = 5×10⁻¹⁰⁷). The paper explicitly highlighted the IL2RA locus as evidence that atopic dermatitis involves systemic immune dysregulation — not just skin-barrier defects — placing it alongside classic HLA and cytokine loci. The T allele risk frequency in the atopic dermatitis cohort was ~12%.

Earlier evidence established this locus in type 1 diabetes: the Type 1 Diabetes Genetics Consortium meta-analysis (Barrett et al. 2009)⁶⁶ Type 1 Diabetes Genetics Consortium meta-analysis (Barrett et al. 2009) identified the same 10p15 region at genome-wide significance (p = 1×10⁻¹³), consistent with the IL2RA locus being a shared hub for autoimmune susceptibility. A 2023 cross-trait GWAS also found rs12251307 among loci shared between rheumatoid arthritis and type 1 diabetes (Wen & Yu 2023)⁷⁷ (Wen & Yu 2023). The variant also reaches genome-wide significance for asthma susceptibility (OR ~1.09, p = 2×10⁻⁹), extending the phenotypic spectrum to atopic disease more broadly. The functional biology underlying all these associations is coherent: Treg dysfunction resulting from impaired CD25 expression or IL-2 signaling permits both autoimmune attack (T1D, RA) and dysregulated type 2 immune responses (atopic dermatitis, asthma) depending on the downstream context.

Practical Actions

The T allele confers a small per-allele risk increase (OR ~1.10 per T copy). In absolute terms, the lifetime risk increase is modest but meaningful in context of a personal or family history of atopic or autoimmune conditions. Carriers cannot directly manipulate CD25 expression, but the downstream biology — Treg function and IL-2 signaling — is modulated by vitamin D status and IL-2 availability. The most clinically actionable implication for T allele carriers is awareness of early-onset warning signs across atopic and autoimmune phenotypes and timely engagement with a dermatologist or immunologist when symptoms arise.

Interactions

rs12251307 is in the same genomic locus as several other IL2RA variants already catalogued: rs2104286⁸⁸ rs2104286 (intron 1, soluble IL-2RA shedding), rs12722489⁹⁹ rs12722489 (intron 1, estrogen-responsive enhancer), rs41295061¹⁰¹⁰ rs41295061 (regulatory, T1D locus), and rs2256774¹¹¹¹ rs2256774 (intronic). These variants are in partial linkage disequilibrium; rs12251307 represents an additional, partially independent signal at the 3' end of the locus. Compound heterozygosity across multiple IL2RA locus variants may further impair Treg function, though the specific interaction effects have not been quantified for this downstream position. The locus also interacts biologically with IL-2 pathway genes including IL2RB¹²¹² IL2RB and IL2¹³¹³ IL2; variants in these genes that reduce IL-2 production or beta-chain signaling would compound the signaling deficit created by impaired CD25 expression.